Moderna(@moderna_tx):We recently received authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for our Phase 1/2 clinical study evaluating mRNA-4194, an investigational mRNA-based vaccine for people with Lynch syndrome, an inherited condition that increases the risk of cancer. David Berman, our Chief Development Officer, sat down for an episode of IR Insights to provide an overview of this innovative program and Moderna’s research in the cancer prevention vaccine space:

Moderna

@moderna_tx

Our mission is to deliver the greatest possible impact to people through mRNA medicines.

加入 December 2013

541 正在關注 145.4K 粉絲

Moderna@moderna_tx

2026.06.08 23:48

We recently received authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for our Phase 1/2 clinical study evaluating mRNA-4194, an investigational mRNA-based vaccine for people with Lynch syndrome, an inherited condition that increases the risk of cancer. David Berman, our Chief Development Officer, sat down for an episode of IR Insights to provide an overview of this innovative program and Moderna’s research in the cancer prevention vaccine space: